Literature DB >> 32649875

Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression.

Yi-Ju Chen1, Theodoros I Roumeliotis2, Ya-Hsuan Chang3, Ching-Tai Chen4, Chia-Li Han5, Miao-Hsia Lin1, Huei-Wen Chen6, Gee-Chen Chang7, Yih-Leong Chang8, Chen-Tu Wu8, Mong-Wei Lin9, Min-Shu Hsieh8, Yu-Tai Wang10, Yet-Ran Chen11, Inge Jonassen12, Fatemeh Zamanzad Ghavidel12, Ze-Shiang Lin13, Kuen-Tyng Lin1, Ching-Wen Chen13, Pei-Yuan Sheu13, Chen-Ting Hung13, Ke-Chieh Huang1, Hao-Chin Yang1, Pei-Yi Lin1, Ta-Chi Yen1, Yi-Wei Lin9, Jen-Hung Wang4, Lovely Raghav14, Chien-Yu Lin3, Yan-Si Chen3, Pei-Shan Wu1, Chi-Ting Lai1, Shao-Hsing Weng1, Kang-Yi Su15, Wei-Hung Chang11, Pang-Yan Tsai11, Ana I Robles16, Henry Rodriguez16, Yi-Jing Hsiao13, Wen-Hsin Chang17, Ting-Yi Sung18, Jin-Shing Chen19, Sung-Liang Yu20, Jyoti S Choudhary21, Hsuan-Yu Chen22, Pan-Chyr Yang23, Yu-Ju Chen24.   

Abstract

Lung cancer in East Asia is characterized by a high percentage of never-smokers, early onset and predominant EGFR mutations. To illuminate the molecular phenotype of this demographically distinct disease, we performed a deep comprehensive proteogenomic study on a prospectively collected cohort in Taiwan, representing early stage, predominantly female, non-smoking lung adenocarcinoma. Integrated genomic, proteomic, and phosphoproteomic analysis delineated the demographically distinct molecular attributes and hallmarks of tumor progression. Mutational signature analysis revealed age- and gender-related mutagenesis mechanisms, characterized by high prevalence of APOBEC mutational signature in younger females and over-representation of environmental carcinogen-like mutational signatures in older females. A proteomics-informed classification distinguished the clinical characteristics of early stage patients with EGFR mutations. Furthermore, integrated protein network analysis revealed the cellular remodeling underpinning clinical trajectories and nominated candidate biomarkers for patient stratification and therapeutic intervention. This multi-omic molecular architecture may help develop strategies for management of early stage never-smoker lung adenocarcinoma.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APOBEC signature; MMP; carcinogen signature; genomics; lung cancer; non-smoker; phosphoproteomics; proteogenomics; proteomics; subtyping

Mesh:

Substances:

Year:  2020        PMID: 32649875     DOI: 10.1016/j.cell.2020.06.012

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  47 in total

Review 1.  Genetic and non-genetic clonal diversity in cancer evolution.

Authors:  James R M Black; Nicholas McGranahan
Journal:  Nat Rev Cancer       Date:  2021-03-16       Impact factor: 60.716

2.  Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutations.

Authors:  Xiaohong Han; Rongrong Luo; Lin Wang; Lei Zhang; Tao Wang; Yan Zhao; Shanshan Xiao; Nan Qiao; Chi Xu; Lieming Ding; Zhishang Zhang; Yuankai Shi
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 3.  Antitumour immunity regulated by aberrant ERBB family signalling.

Authors:  Shogo Kumagai; Shohei Koyama; Hiroyoshi Nishikawa
Journal:  Nat Rev Cancer       Date:  2021-01-18       Impact factor: 60.716

4.  A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving TP53 and epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas (LUAD).

Authors:  Ying Zhu; Yu-Biao Guo; Di Xu; Jing Zhang; Zhen-Guo Liu; Xi Wu; Xiao-Yu Yang; Dan-Dan Chang; Min Xu; Jing Yan; Zun-Fu Ke; Shi-Ting Feng; Yang-Li Liu
Journal:  Ann Transl Med       Date:  2021-04

5.  Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial.

Authors:  Zhenzhou Yang; Yan Zhang; Rongqing Li; Abulimiti Yisikandaer; Biyong Ren; Jianguo Sun; Jianjun Li; Long Chen; Ren Zhao; Juying Zhang; Xuefeng Xia; Zhongxing Liao; David P Carbone
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

6.  A systematic dissection of the epigenomic heterogeneity of lung adenocarcinoma reveals two different subclasses with distinct prognosis and core regulatory networks.

Authors:  Chongze Yuan; Haojie Chen; Shiqi Tu; Hsin-Yi Huang; Yunjian Pan; Xiuqi Gui; Muyu Kuang; Xuxia Shen; Qiang Zheng; Yang Zhang; Chao Cheng; Hui Hong; Xiaoting Tao; Yizhou Peng; Xingxin Yao; Feilong Meng; Hongbin Ji; Zhen Shao; Yihua Sun
Journal:  Genome Biol       Date:  2021-05-17       Impact factor: 13.583

Review 7.  The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment.

Authors:  Henry Rodriguez; Jean Claude Zenklusen; Louis M Staudt; James H Doroshow; Douglas R Lowy
Journal:  Cell       Date:  2021-04-01       Impact factor: 41.582

Review 8.  Quantitative proteomics characterization of cancer biomarkers and treatment.

Authors:  Xiao-Li Yang; Yi Shi; Dan-Dan Zhang; Rui Xin; Jing Deng; Ting-Miao Wu; Hui-Min Wang; Pei-Yao Wang; Ji-Bin Liu; Wen Li; Yu-Shui Ma; Da Fu
Journal:  Mol Ther Oncolytics       Date:  2021-04-20       Impact factor: 7.200

9.  Somatic mutation subtypes of lung adenocarcinoma in East Asian reveal divergent biological characteristics and therapeutic vulnerabilities.

Authors:  Wai-Kok Choong; Ting-Yi Sung
Journal:  iScience       Date:  2021-05-07

10.  Identification of Novel Genomic-Variant Patterns of OR56A5, OR52L1, and CTSD in Retinitis Pigmentosa Patients by Whole-Exome Sequencing.

Authors:  Ting-Yi Lin; Yun-Chia Chang; Yu-Jer Hsiao; Yueh Chien; Ying-Chun Jheng; Jing-Rong Wu; Lo-Jei Ching; De-Kuang Hwang; Chih-Chien Hsu; Tai-Chi Lin; Yu-Bai Chou; Yi-Ming Huang; Shih-Jen Chen; Yi-Ping Yang; Ping-Hsing Tsai
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.